Alpha‑GPC to boost thinking, mood, and athletic performance
Official title: A Randomised, Double-Blind, Placebo-Controlled Study on the Effects of Alpha-Glycerophosphocholine (α-GPC) on Cognitive Function and Sports Performance in Adults
Run by Nanjing Nutrabuilding Bio-tech Co., Ltd. · NCT07267845 · Data updated 2026-11-12
This study tests whether taking 350 mg of Alpha‑GPC each day for six weeks can improve thinking, mood, and athletic performance in healthy adults aged 25–55.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 55 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Nanjing Nutrabuilding Bio-tech Co., Ltd. Academic / other |
| Locations | 1 site (Cork, County Cork) |
| Status | Recruiting |
| Started | October 21, 2025 |
| Main results expected | May 15, 2026 |
| Study ends | July 5, 2026 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07267845 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy, recreationally active adults aged 25–55 with BMI 18.5–32 kg/m2 who are not highly trained competitive athletes and can follow diet/exercise restrictions and attend study visits.
✕Probably not a fit
Highly trained competitive athletes, pregnant or breastfeeding people, or those outside the specified age, weight, or BMI ranges are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double‑blind, placebo‑controlled trial will give healthy adults aged 25–55 either 350 mg of Alpha‑GPC or a matching placebo daily for six weeks. Cognitive performance will be measured with tests including the Stroop Test, Go/No‑Go, SART, and DSST, while sports performance will assess upper‑ and lower‑body measures. Participants will self-report mood, energy, and motivation, and the study will monitor safety and tolerability compared with placebo. The trial is sponsored by Nanjing Nutrabuilding Bio‑tech and conducted at Atlantia Clinical Trials in Cork, Ireland.
Why it matters
Potential benefit: If successful, daily Alpha‑GPC could modestly improve short‑term attention, perceived energy/motivation, and measures of strength or power in recreationally active adults.
How similar studies have gone: Small prior studies of Alpha‑GPC have reported some improvements in power output and certain cognitive measures, but results are mixed and larger confirmatory trials are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be able to give written informed consent. * Be in good health as determined by the investigator. * Age between 25 and 55 years (inclusive). * Body Mass Index of 18.5-32.0 kg/m2 (inclusive). * Body weight of at least 54 kilograms. * Muscle strengthening activities 2-3 time per week or participation in recreational or local level moderate intensity activity for at least 2 years. * Normotensive (resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg). * Willing to duplicate their previous 24-hr diet, refrain from alcohol and caffeine for 24-hr prior to each visit, refrain from exercise 48-hr prior to each visit. * Refrain from consuming beef liver, chicken liver, eggs, fish, wheat germ and soybeans, butter beans 24-hrs prior to Visit 2 and Visit 3. Exclusion Criteria: * Highly trained or competitive athletes. * Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding. * Female participants who are currently breastfeeding. * Female participants who are planning to become pregnant during the study period. * Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product. * Participants with history of drug and/or alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\>11 units for women; \>17 units for men); alcohol/substance abuse disorder). * Caffeine intake of three or more cups of coffee or equivalent (\>400 mg) per day. * Current smokers or users of any nicotine products in the past 4-weeks. * Has food allergies or other issues with foods that would preclude intake of the Study Products. * Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. * History of malignancy in the previous 5 years except for non-melanoma skin cancer. * Diagnosed, uncontrolled psychiatric disorder. * Hepatorenal, musculoskeletal, autoimmune, or neurologic disease. * Prior gastrointestinal bypass surgery (excluding appendectomy). * Gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism. * Chronic inflammatory condition or disease. * History of severe or chronic musculoskeletal pain or injury. * History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD. * Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. * Use CNS stimulants or anxiety or ADHD medication. * Use corticosteroids (oral, subcutaneous, intramuscular, or transdermal only). * Use testosterone replacement therapy (ingestion, injection, or transdermal). * Current or recent use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. * Use creatine, BCAA, HMB, betaine, beta-alanine, in the past 2 weeks. * Use choline supplements (e.g. choline bitartrate, phosphatidylcholine, citicholine) in the past 4 weeks. * Use omega-3, ginkgo biloba, ginseng, L-theanine, Lion's Mane, ashwagandha in the past 4 weeks. * Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study. * Participants may be participating in other clinical studies.
Where it's running
-
Atlantia Clinical Trials
Cork, County Cork, Ireland Recruiting
Study contacts
- Study coordinator: Nontokozo Yusuff, MBChC
- Email: nyusuff@atlantiatrials.com
- Phone: +353 (0)21-430 7442
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How age affects germinal center responses after flu and rabies vaccines
Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).
-
Magnetic field maps with NV sensors for non-invasive heart measurements
This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.
-
Methylation analyses using home-based self-sampling in women with and without gynecological disease
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.
-
Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products
This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.
-
A safe, carefully dosed test of TBD11 in healthy adults
This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.
-
Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm
This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.